Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.
Antimicrob Agents Chemother
; 58(10): 6311-4, 2014 Oct.
Article
in En
| MEDLINE
| ID: mdl-25092700
ABSTRACT
Ceftolozane is a novel cephalosporin with activity against drug-resistant pathogens, including Pseudomonas aeruginosa and Streptococcus pneumoniae. The in vivo investigation reported here tested the limits of this drug against 20 P. aeruginosa and S. pneumoniae isolates across a wide MIC range and defined resistance mechanisms. The times above the MIC (T>MIC) targets for stasis and 1- and 2-log reductions were 31%, 39%, and 42% for P. aeruginosa and 18%, 24%, and 27% for S. pneumoniae, respectively. The 1-log endpoint was achieved for strains with MICs as high as 16 µg/ml.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pseudomonas aeruginosa
/
Streptococcus pneumoniae
/
Cephalosporins
/
Anti-Bacterial Agents
Language:
En
Journal:
Antimicrob Agents Chemother
Year:
2014
Document type:
Article
Affiliation country:
United States